Free Trial Information
BioCentury | Apr 3, 2021
Product Development

Target diversity in the CAR NK and CAR NKT pipeline: Data Byte

...enter the clinic within the next two years.TARGETSCD33 (SIGLEC3) EGFR (ErbB1; HER1) – Epidermal growth factor receptorFLT3 (CD135...
Read More
BioCentury | Mar 31, 2021
Regulation

March 31 Quick Takes: Basket of EU approvals includes MS, SMA drugs; plus Amarin, AbbVie, Cara-Vifor

The European Commission approved Kesimpta ofatumumab from Novartis AG (NYSE:NVS; SIX:NOVN) to treat relapsing forms of multiple sclerosis. The subcutaneously administered drug was originally developed by Genmab A/S (CSE:GMAB; NASDAQ:GMAB). Evrysdi risdiplam, an oral small molecule...
Read More
BioCentury | Feb 27, 2021
Regulation

Nod for Roche’s oral SMA drug among CHMP’s latest opinions: Data Byte

February’s recommendations by EMA’s CHMP included a nod in favor of Roche’s Evrysdi risdiplam, setting the drug up to become the first oral spinal muscular atrophy therapy in Europe.  CHMP recommended, under its accelerated assessment...
Read More
BioCentury | Feb 9, 2021
Product Development

Feb. 8 Quick Takes: FDA approves TG’s lymphoma therapy; plus uniQure, Astellas, BMS, Viiv, Avrobio and Veru

...from China’s National Medical Products Administration to treat relapsed or refractory acute myeloid leukemia with a FLT3...
...since the approval of Jakafi ruxolitinib from Incyte Corp. (NASDAQ:INCY). BMS gained the JAK2 and FLT3...
...in April, with data coming in 4Q21.TARGETSCSNK1E (CKIε) – Casein kinase 1 εFLT3 (CD135) - FMS-like tyrosine kinase 3...
Read More
BioCentury | Feb 5, 2021
Emerging Company Profile

Deals with Allogene, ADC reflect Overland’s ambition to tap parent Hillhouse’s network to bring innovation to China

...to specified Allogene candidates targeting BCMA, CD70, FLT3...
...like canonical Notch ligand 3FLT3 (CD135) – FMS-like tyrosine kinase 3 Jeff...
Read More
BioCentury | Dec 15, 2020
Deals

Hillhouse’s Overland builds momentum with second marquee China deal with Allogene

...to specified Allogene candidates targeting BCMA, CD70, FLT3...
Read More
BioCentury | Dec 5, 2020
Product Development

Bispecifics spring ahead at this year’s ASH, SITC

...LLC will share preclinical data for a FLT3...
...factor receptorFcRH5 (FCRL5) – Fc receptor-like 5FLT3 (CD135...
Read More
BioCentury | Nov 19, 2020
Finance

VCs back Celleron spinout with €37M to develop former Roche asset for rare joint disorder

...Sankyo Co. Ltd. (Tokyo:4568). The label of that drug, a small molecule inhibitor of CSF1R, c-Kit and FLT3, includes...
...Stem cell factor (SCF) receptor tyrosine kinaseCSF1R (C-FMS; CD115) Colony-stimulating factor 1 receptorFLT3 (CD135) - FMS-like tyrosine kinase 3 Paul...
Read More
BioCentury | Sep 16, 2020
Deals

Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology

...formed Cullinan Florentine to develop CLN-049, an FLT3...
...– Fibroblast growth factor 21FLT3 (CD135) - FMS-like tyrosine kinase 3 BC...
Read More
BioCentury | Sep 3, 2020
Finance

Sept. 2 Quick Takes: Taysha files for IPO; plus DCVC’s Barclay joins Cohen’s Point72, Erasca, Deep Longevity and more

...received €4.5 million ($5.4 million) in series A financing led by V-Bio Ventures to develop FLT3...
...2014, the company counts Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. among its partners.TARGETSFLT3 (CD135) - FMS-like tyrosine kinase 3 BC...
Read More
Items per page:
1 - 10 of 699